Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Circassia Pharmaceuticals ( (GB:NIOX) ) has shared an update.
NIOX Group plc, a company listed on the AIM market, announced an update regarding its total voting rights. As of July 31, 2025, the company has 417,783,853 ordinary shares in issue, each carrying one voting right, with no shares held in treasury. The recent exercise of options by employees resulted in the issuance of 31,928 new ordinary shares. These shares have been admitted through the company’s block listing and rank equally with existing shares. This update is significant for shareholders as it affects the denominator used for calculating their interests under FCA’s Disclosure and Transparency Rules.
The most recent analyst rating on (GB:NIOX) stock is a Buy with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.
Spark’s Take on GB:NIOX Stock
According to Spark, TipRanks’ AI Analyst, GB:NIOX is a Outperform.
The overall stock score of 74 reflects solid financial performance and positive corporate events, which are slightly offset by a high P/E ratio and moderate technical momentum. The company’s strategic initiatives and strong cash flow management are key strengths, positioning it well in the industry.
To see Spark’s full report on GB:NIOX stock, click here.
More about Circassia Pharmaceuticals
Average Trading Volume: 1,029,305
Technical Sentiment Signal: Strong Buy
Current Market Cap: £292.2M
For an in-depth examination of NIOX stock, go to TipRanks’ Overview page.